Clinical study of malignant lymphomas in the oral and maxillofacial region over the past 6 years

• Published in: Japanese Journal of Oral and Maxillofacial Surgery Vol. 38; no. 12; pp. 1859 - 1866
• Main Authors: HANAZAWA, Yasuo, MABASHI, Toshinori, AKIZUKI, Kazuki, UCHIYAMA, Satoshi, ITOH, Kohsuke, KANAZAWA, Harusachi, SATO, Kenichi
• Format: Journal Article
• Language: English
• Published: Japanese Society of Oral and Maxillofacial Surgeons 1992
• Subjects: immunophenotype; non-Hodgkin's lymphoma; Rye and LSG classification
• ISSN: 0021-5163; 2186-1579; 2186-1579
• DOI: 10.5794/jjoms.38.1859

Ten patients with malignant lymphomas in the oral and maxillofacialregion who were treated at our department during the period from 1986 to 1991 underwent clinical biometric analysis. The results were as follows: 1. The subjects consisted of 4 males and 6 females aged from 39-82 years (mean age 62.6 years). 2. In all cases, the chief complaints or initial symptoms were swelling or tumor formation in the affected areas and pain was present in 3 cases. 3. The presumed primary site of the tumor was the submaxillar or cervical lymphnodes in 5 cases, the gingivae or alveoli of the mandible in 3, the hard palate in 1 and the tongue in 1. 4. According to the Ann Arbor staging classification, four cases were in stage I, two stage II, one stage III and three stage IV, respectively. 5. The histopathological diagnosis, defined by the Rye (Hodkin's disease) and LSG (non-Hodgkin's lymphoma) classification, was lymphocytic predominance type of Hodgkin'sdisease in 1 case and non-Hodgkin's lymphoma in the other 9 cases. The tumor cell types were diffuse small in 1 case, diffuse medium in 1, diffuse mixed in 1 and diffuse large in 6, respectively. 6. Immunophenotypic analysis of surface markers, preformed in 7 cases, revealed that one case was T-cell type and the others were B-cell type. 7. For treatment, radiotherapy alone was applied in stage I (4 cases) and stage II (1), chemotherapy alone in stage IV (3), and combined treatment in stage II (1), and III (1), respectively. Eight patient were alive and 2 cases have died as of May 1992. The overall 3-year survival rate was 73%.